CoChat

Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia

Open access
Holland, Thomas L., Cosgrove, Sara E., Doernberg, Sarah B., Jenkins, Timothy C., Turner, Nicholas A., Boucher, Helen W., Pavlov, Oleksander, Titov, Ivan, Kosulnykov, Serhii, Atanasov, Boyko, Poromanski, Ivan, Makhviladze, Manana, Anderzhanova, Anastasia, Stryjewski, Martin E., Assadi Gehr, Maziar, Engelhardt, Marc, Hamed, Kamal, Ionescu, Daniel, Jones, Mark, Saulay, Mikael, Smart, Jennifer, Seifert, Harald, Fowler, Vance G. · 2023 · New England Journal of Medicine
Cited by 115

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Ceftobiprole is a cephalosporin that may be effective for treating complicated Staphylococcus aureus bacteremia, including methicillin-resistant S. aureus. Download a PDF of the Research Summary. In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or daptomycin at a dose of 6 to 10 mg per kilogram of body weight intravenously every 24 hours plus optional aztreonam (at the discretion of the trial-site investigators). The primary outcome, overall treatment success 70 days after randomization (defined as survival, bacteremia clearance, symptom improvement, no new S. aureus bacteremia–related complications, and no receipt of other potentially effective antibiotics), with a noninferiority margin of 15%, was adjudicated by a data review committee whose members were unaware of the trial-group assignments. Safety was also assessed. Of 390 patients who underwent randomization, 387 (189 in the ceftobiprole group and 198 in the daptomycin group) had confirmed S. aureus bacteremia and received ceftobiprole or daptomycin (modified intention-to-treat population). A total of 132 of 189 patients (69.8%) in the ceftobiprole group and 136 of 198 patients (68.7%) in the daptomycin group had overall treatment success (adjusted difference, 2.0 percentage points; 95% confidence interval [CI], −7.1 to 11.1). Findings appeared to be consistent between the ceftobiprole and daptomycin groups in key subgroups and with respect to secondary outcomes, including mortality (9.0% and 9.1%, respectively; 95% CI, −6.2 to 5.2) and the percentage of patients with microbiologic eradication (82.0% and 77.3%; 95% CI, −2.9 to 13.0). Adverse events were reported in 121 of 191 patients (63.4%) who received ceftobiprole and 117 of 198 patients (59.1%) who received daptomycin; serious adverse events were reported in 36 patients (18.8%) and 45 patients (22.7%), respectively. Gastrointestinal adverse events (primarily mild nausea) were more frequent with ceftobiprole. Ceftobiprole was noninferior to daptomycin with respect to overall treatment success in patients with complicated S. aureus bacteremia. (Funded by Basilea Pharmaceutica International and the U.S. Department of Health and Human Services; ERADICATE ClinicalTrials.gov number, NCT03138733.) QUICK TAKE VIDEO SUMMARYCeftobiprole for Complicated S. aureus Bacteremia 02:15

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2300220

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Holland, T. L., Cosgrove, S. E., Doernberg, S. B., Jenkins, T. C., Turner, N. A., Boucher, H. W., Pavlov, O., Titov, I., Kosulnykov, S., Atanasov, B., Poromanski, I., Makhviladze, M., Anderzhanova, A., Stryjewski, M. E., Assadi Gehr, M., Engelhardt, M., Hamed, K., Ionescu, D., Jones, M., Saulay, M., Smart, J., Seifert, H., & Fowler, V. G.
Venue
New England Journal of Medicine
Published
2023-10-12
Volume
389
Issue
15
Pages
1390-1401
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4387077543
Cited by
115
References
2
FWCI
21.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.